AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05755971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination taping
Description: Elastic and rigid tapes applied together for six weeks
Study NCT06053294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS- Beverage
Description: Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06053294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Fast
Description: (CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06256523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 0.5mg-13mg
Study NCT06256523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study NCT06053294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CS+Slow
Description: (CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
Study NCT06280573 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wim Hoff method
Description: breathing exercises, cold exposure, and meditation
Study NCT05765526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
Study NCT06374316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceiling-Mounted Air Purifiers
Description: The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
Study NCT06374316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Air Purifiers
Description: The devices will be turned on every working day except Tuesdays. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
Study NCT06374316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable or Ceiling Mounted Air Purifiers
Description: The Ceiling-Mounted and Portable devices will alternate weekly between being activated and deactivated in the three classrooms. Each classroom will also have three weeks with no purifier activated.This alternating pattern aims to assess the impact of the various air purifiers on air quality. Air purifiers will be set at levels perceived as acceptable by both teachers and students during operational hours.
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Continuous Infraclavicular Brachial Plexus Block
Description: 20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Continuous Femoral Nerve Block
Description: 20cc of 0.25% bupivacaine + 1:200K epinephrine will be administered at start of case, 20cc of 0.25% bupivacaine + 1:200K epinephrine at end of case, and 6cc/hr of 0.25% bupivacaine at post-op \[administered by anesthesiologist\]
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided Pudendal Nerve Block
Description: 20-40cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist, pre-incision\]
Study NCT05579184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Ludotadipep
Description: Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection
Study NCT05360537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec / Liraglutide Injectable Product
Description: administration of Insulin Degludec/Liraglutide
Study NCT05360537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administration of glargine insulin
Study NCT04979338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5% with or without 1:200K epinephrine
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided Transversus Abdominis Plane Block
Description: 40-60cc of 0.25% bupivacaine + 1:200K epinephrine \[administered by anesthesiologist post-op or at end of surgery\]
Study NCT05056194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valiloxybate
Description: XW10172 MR Granules for Oral Suspension
Study NCT05056194 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Granules for Oral Suspension
Study NCT05352737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: methylmalonic acid testing
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral spermatic cord block
Description: 10cc per spermatic cord of 0.5% bupivacaine \[administered by surgeon @ intraop\]
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs I & II Block
Description: 0.25% bupivacaine: 15-30mL per side for Pecs I-III
Study NCT04979338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: 0.25% or 0.5% bupivacaine into the appropriate surgical site
Study NCT03095157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fractionated marine lipid concentrate derived from anchovy and sardine oil
Description: Patients will be randomized to receive perioperative treatment versus placebo
Study NCT03095157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fractionated marine lipid concentrate derived from anchovy and sardine oil
Description: Patients will be randomized to receive perioperative treatment versus placebo
Study NCT05131659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function group therapy
Description: This executive function group therapy curriculum for adolescents uses cognitive behavioral therapy techniques, and focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support.
Study NCT04999891 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive tests
Description: Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, NuDESC, 3D-CAM.
Study NCT05774262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Description: Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
Study NCT05774262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioneuroablation (CNA)
Description: Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate > 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called.
Study NCT06452121 — intervention group
Intervention type: OTHER
Intervention: triglyceride glucose index
Description: The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG
Study NCT05704608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Exercises on a treadmill at different speeds and inclination were performed.
Study NCT05901142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based multi-phasic, multi-modal intervention
Description: Pre-op: 2\*60min supervised; 1\*30min unsupervised walking sessions per week Supervised session: Aerobic: 8\*60secs star jump, squat thrust, high knees with 90sec rest. Elastic resistance: 2\*10-12reps of chest press, seated row, leg press, 'lat' pulldown, and either abdominal flexion or lumbar extension-alternated, with 60-90sec rest. Targeted physiotherapy: general breathing exercises, active-assisted range of motion (RoM) exercises, and active-resisted RoM exercises~Postop: 1\*60min supervised exercise; unsupervised walking \[2\*30min weeks 1-2; 3\*30min week 3; 4\*30min weeks 4-6\] session per week Supervised session: Aerobic: As above using full body extension, squat jump, static sprint in week 1-4. Progressed to those performed preoperatively from week 5. Elastic resistance: As above from week 4, performed 3\*week. Targeted physiotherapy: As above, with active-assisted RoM progressing from 1\*10reps in week 1, to 2\*10reps in weeks 2-4, and 3\*10reps in weeks 4-6
Study NCT04955236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Partial scalp block
Description: Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.).
Study NCT04955236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1µg/kg/hr. of intravenous fentanyl infusion will be administered. A syringe filled with 20 ml of normal saline will be prepared and 3 ml of normal saline will be injected at the same points of the partial scalp block previously described
Study NCT05231551 — intervention group
Intervention type: PROCEDURE
Intervention: Placental tissues
Description: Placental tissues are collected after aspiration of abortion products. They are treated immediately in order to isolate placental stem cells. Organoid culture is established and the obtained embryoids are cultured in monophasic or biphasic oxygen conditions. Extra organoids are cryopreserved in liquid nitrogen
Study NCT06498167 — intervention group
Intervention type: DRUG
Intervention: Upadacitinib
Description: Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).
Study NCT06501677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WBI
Description: The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness.
Study NCT06501677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Description: The WBI will comprise of four sessions focusing on CRAFT principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to the DP (PPR; i.e., actively listening, showing understanding, expressing interest in what their DP is thinking and feeling, and trying to see where the DPs is coming from), (3) understanding the DP's drinking reinforcers, and (4) supporting the DP if they want help and engaging in positive, healthy activities with the DP. ' partner.~Each module will take \~20-30 minutes and each session will: (1) instill optimism in CPs, (2) be solution-focused, (3) emphasize that the CP is not responsible for the DP's behaviors, and (4) use a nonjudgmental, non-confrontational, empathetic style. The WBI intervention is focused on reduced drinking in the DP and improved CP wellness.
Study NCT04839484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Product
Description: up to 2cc per injection of filler placed into nasolabial fold.
Study NCT04839484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: up to 2cc per injection of filler placed into nasolabial fold.
Study NCT06151769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical pomegranate seed oil
Description: Intervention groups: In addition to the routine care of the patients, Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. 1.5 cc will be applied to the back of the sacrum and 1 cc to each heel, using circular movements without pressure for approximately 5 seconds. It will be waited for 2-3 minutes for the body to absorb the oil, then it will be touched and removed with a napkin without any rubbing movements. The application will be applied for 6 days. The patient follow-up form will be completed by the researcher every day at 12:00 noon. Again, on the 6th day of the application, evaluation surveys with the Braden risk assessment scale will be conducted by the researcher.
Study NCT06151769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sesame oil
Description: Sesame oil
Study NCT05035277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.
Study NCT05035277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Standard dose apixaban will be one of the options for the patients in the experimental arm.
Study NCT05035277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.
Study NCT05035277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Standard dose edoxaban will be one of the options for the patients in the experimental arm.
Study NCT04065360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive behavioural family intervention (CBFI)
Description: four-week, four-session CBT-based family intervention programme
Study NCT04065360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual group psychoeducation
Description: Treatment as usual in the institution studied
Study NCT05516979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg AP1189
Description: AP1189 tablets for oral use
Study NCT05516979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for oral use
Study NCT05185765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
Study NCT05204901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion and withdrawal of a magnetic-tipped wire into the lumen of the nasogastric tube for tracking of its position
Description: In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
Study NCT04754906 — intervention group
Intervention type: OTHER
Intervention: Sequence 1
Description: perform arm movements towards a target
Study NCT04754906 — intervention group
Intervention type: OTHER
Intervention: Sequence 2
Description: judge the verticality of an object
Study NCT04754906 — intervention group
Intervention type: OTHER
Intervention: Sequence 3
Description: In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
Study NCT04668885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity.
Study NCT05170581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined with Platinum-containing Chemotherapy
Description: Admininster Sintilimab and platinum-containing chemotherapy in neoadjuvant treatment of resectable stage ⅡB～ⅢA Non-small Cell Lung Cancer
Study NCT05551234 — intervention group
Intervention type: OTHER
Intervention: Regular exchanges
Description: The seniors and childrens will meet once a week, for 7 months, over a period of one and a half hours, outside school hours (4:30 p.m. to 6:00 p.m.) and school holidays.
Study NCT05250999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin stretch sensory stimuli
Description: Skin stretch sensory stimuli will be exerted by a piece of kinesio tape that as applied above right and left lateral malleolus on posterior leg and on both side of spinous process of second thoracic vertebrae till 15cm below for 24 hours a day, 5 days/ week for 6 weeks along with conventional physiotherapy.
Study NCT05250999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical nerve stimulation
Description: TENS will be applied to patient while in sitting position for 30 minutes, twice a week, and for 6 weeks (12 treatment sessions along with conventional physiotherapy). A maximum of 25 m amp electrical stimulation with a biphasic square-wave pattern and a pulse width of 0.5ms in a continuous duty cycle will be used. The intensity of the electrical stimulation will be regulated to the high tolerable level without initiating muscle contractions.
Study NCT06156332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib、serplulimab
Description: surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment.
Study NCT05186675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superselective adrenal arterial embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
Study NCT06432855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: 20 ml-blood sample
Study NCT06432855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saliva collection
Description: saliva sample